Studies of mutational status and gene usage of the IgH V region (IGHV) of the BCR on CLL cells have not only revealed a relationship between IGHV mutation and clinical course, but have also led to wide acceptance of a key role for BCR engagement in disease pathogenesis and clinical behavior (1). Here, BCR is linked to B-cell chronic lymphocytic leukemia.